Mode
Text Size
Log in / Sign up

Pulmonary Tuberculosis

Part of Tuberculosis

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pulmonary Tuberculosis

35 trials tracked for Pulmonary Tuberculosis: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 1047 citations.

35Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5 Phase 2 21 Phase 1 4 Other / NA 5
  1. Phase 3 A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB Completed · 1,047 cited
  2. Phase 3 Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Completed · 585 cited
  3. Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Completed · 61 cited
  4. Phase 3 Optimization of the TB Treatment Regimen Cascade Completed
  5. Phase 3 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Completed
  6. Phase 2 Linezolid to Treat Extensively-Drug Resistant Tuberculosis Completed
Show 29 more trials
  1. Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) Completed
  2. Phase 2 Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design Completed
  3. Phase 2 Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion Completed
  4. Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) Completed
  5. Phase 2 PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis Completed
  6. Phase 2 Linezolid Dosing Strategies in Drug-Resistant TB Completed
  7. Phase 2 Assessing PA-824 for Tuberculosis (the APT Trial) Completed
  8. Phase 2 Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) Completed
  9. Phase 2 Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis Completed
  10. Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) Completed
  11. Phase 2 Using Biomarkers to Predict TB Treatment Duration Completed
  12. Phase 2 Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis Completed
  13. Phase 2 A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Completed
  14. Phase 2 StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis Completed
  15. Phase 2 A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Completed
  16. Phase 2 PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Completed
  17. Phase 2 Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence Completed
  18. Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) Completed
  19. Phase 2 Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB Completed
  20. Phase 2 INSTI's For The Management of HIV-associated TB Completed
  21. Phase 1 Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers Completed
  22. Phase 1 A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults Completed
  23. Phase 1 A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults Completed
  24. Phase 1 Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Completed
  25. N/A A Clinical Risk Score for Early Management of TB in Uganda Completed
  26. N/A Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda Completed
  27. N/A Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia Completed
  28. N/A GeneXpert Performance Evaluation for Linkage to Tuberculosis Care Completed
  29. N/A Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pulmonary Tuberculosis: what the trials found

Several trials evaluated the efficacy of Pretomanid in treating tuberculosis. One study demonstrated that a significant number of participants achieved culture-negative status by 8 weeks (p < 0.001) 5. Additionally, clinical data showed that Pretomanid was associated with specific changes in sperm count at 12 and 44 weeks 10.

Bedaquiline was evaluated for treatment failure; results showed varying proportions of patients experiencing bacteriologic or clinical failure at both 6 months and 24 months post-treatment 3.

PA-824 demonstrated significant differences in time to culture conversion on solid media (p=0.02) 15, while its impact on liquid medium conversion was not statistically significant (p=0.10) 15. Furthermore, PA-824 showed consistent early bactericidal activity (EBA) across multiple measurements of daily rate of change in log10 CFUs on solid media 21.

Safety data for a multi-drug regimen including Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide, and Rifampicin reported 111 to 127 patients with Grade 3 or 4 adverse events 7.

Recent results — preliminary, needs further review

  • Biktarvy was evaluated in a Phase 2 trial 8.
  • Linezolid (600 mg) was assessed for conversion to stable culture and safety; results showed no significant difference in the proportion of patients requiring permanent discontinuation due to adverse events or intolerance (p=0.58 and p=0.82 respectively) 1.

For the clinician treating this condition

  • Pretomanid is associated with high rates of culture-negative status at 8 weeks 5 and measurable impacts on sperm count 10.
  • PA-824 shows statistically significant results for conversion on solid media but not on liquid media 15, while demonstrating consistent early bactericidal activity 21.
  • Linezolid (600 mg) showed no significant difference in treatment discontinuation rates due to adverse events or intolerance compared to the control group 1.

AI synthesis of 8 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Tuberculosis

Related studies from across the Tuberculosis family.

Meta-analysis-guided sampling plan targets 14 zoonotic and animal diseases across India
Neurology Meta-analysis
Meta-analysis-guided sampling plan targets 14 zoonotic and animal diseases across India New sampling plan helps track diseases jumping from animals to humans
This meta-analysis pools prevalence estimates for 10 zoonotic and 4 transboundary animal diseases in India, reporting a range of 4 to 30% ac…
A new plan for monitoring animal diseases in India helps track infections like Q-fever and scrub typhus before they spread to people.
Multi-scale computational methods identify pivotal tuberculosis vulnerabilities and predict drug resistance with high fidelity
Drug Pipeline Sys. Review
Multi-scale computational methods identify pivotal tuberculosis vulnerabilities and predict drug resistance with high fidelity Computational Methods Identify New Targets for Tuberculosis Treatment
This systematic review evaluates multi-scale computational methods including machine learning and molecular dynamics for tuberculosis drug d…
New computer modeling techniques are identifying key targets and predicting drug resistance to help speed up the development of tuberculosis…
Host-directed therapy including metformin and statins may modulate immune response in tuberculosis patients
Allergy & Immunology Sys. Review
Host-directed therapy including metformin and statins may modulate immune response in tuberculosis patients Repurposed Drugs Like Metformin May Help Fight Tuberculosis
This narrative review explores host-directed therapy (HDT) as an adjunctive strategy to modulate immune responses and limit immunopathology …
New research explores how host-directed therapies, including common drugs like metformin and statins, could help the body fight tuberculosis…
3HP with SMS reminders increases treatment completion to 84.9% compared to 65.4% for 4RIF
Infectious Disease RCT
3HP with SMS reminders increases treatment completion to 84.9% compared to 65.4% for 4RIF SMS reminders help more people finish tuberculosis treatment
This randomized controlled trial of 210 individuals with tuberculosis infection found that 3HP with SMS reminders resulted in a higher treat…
A new trial shows that a shorter treatment plan paired with text message reminders helps more people finish their tuberculosis medication.
Tobacco smoking history increases odds of antibiotic-resistant infections including tuberculosis-related resistance
Infectious Disease Meta-analysis
Tobacco smoking history increases odds of antibiotic-resistant infections including tuberculosis-related resistance Tobacco smoking increases risk of antibiotic-resistant bacterial infections
This meta-analysis of more than 35,000 participants indicates that tobacco smoking history is associated with higher odds of antibiotic-resi…
A large review of over 35,000 people shows that a history of smoking significantly increases the risk of developing drug-resistant infection…
Pre-XDR-TB affects 3% and XDR-TB 1% of MDR-TB patients in Ethiopia
Infectious Disease Meta-analysis
Pre-XDR-TB affects 3% and XDR-TB 1% of MDR-TB patients in Ethiopia Drug-Resistant TB Strains Affect 4% of Ethiopian MDR-TB Patients
This meta-analysis estimates the prevalence of pre-extensively drug-resistant (Pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-…
About 4 in 100 MDR-TB patients in Ethiopia also carry harder-to-treat TB strains, a new analysis finds.
Gestational HIV exposure does not increase tuberculosis disease risk in children who are HIV-exposed uninfected
Infectious Disease Meta-analysis
Gestational HIV exposure does not increase tuberculosis disease risk in children who are HIV-exposed uninfected Comparing Tuberculosis Risk in Children Exposed to HIV During Pregnancy
This meta-analysis of 18 studies evaluated tuberculosis risk in children who are HIV-exposed uninfected (cHEU) compared to HIV-unexposed uni…
New data shows that children exposed to HIV before birth have similar tuberculosis risks as children never exposed.
Community health workers support infectious disease management and PrEP navigation in agricultural communities
Neurology Sys. Review
Community health workers support infectious disease management and PrEP navigation in agricultural communities Community health workers help farm workers manage infectious diseases
This mini-review examines the role of community health workers (CHWs) in managing infectious diseases among California agricultural workers.…
Community health workers can help farm workers manage serious infections like HIV, tuberculosis, and hepatitis through direct outreach and n…
Short course regimens 3HP, 4HR, and 4R show higher adherence and lower active cases than 9H
Pediatrics Sys. Review
Short course regimens 3HP, 4HR, and 4R show higher adherence and lower active cases than 9H Short Treatment Courses May Reduce Tuberculosis Cases in Children
This network meta-analysis evaluates treatment regimens for children and adolescents with TB infection. The study finds that 4HR reduces act…
New analysis suggests shorter drug regimens for children with tuberculosis may improve treatment completion and reduce the number of active …
Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TB
Allergy & Immunology Meta-analysis
Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TB New Blood Test Marker Shows Promise for Detecting Hidden Tuberculosis Infections
This meta-analysis of 24 studies (2,014 participants) evaluated Mycobacterium tuberculosis antigen-induced interferon-gamma-inducible protei…
A new protein marker in the blood helps doctors identify people with hidden tuberculosis infections more accurately.
Comprehensive pulmonary rehabilitation may improve exercise capacity and quality of life in post-tuberculosis lung disease
Neurology Sys. Review
Comprehensive pulmonary rehabilitation may improve exercise capacity and quality of life in post-tuberculosis lung disease Comprehensive Pulmonary Rehabilitation May Improve Life After Tuberculosis
This narrative review examines the role of comprehensive pulmonary rehabilitation for individuals with post-tuberculosis lung disease. The a…
Comprehensive pulmonary rehabilitation programs may improve exercise capacity and quality of life for people living with lung disease after …
Fluoroquinolone resistance acquired more frequently during TB treatment than other anti-TB drugs
Infectious Disease Meta-analysis
Fluoroquinolone resistance acquired more frequently during TB treatment than other anti-TB drugs Bacteria develop resistance to fluoroquinolones more often during tuberculosis treatment
This meta-analysis analyzed 5882 high-quality genomes from 1044 patients to identify MTBC mutations during infection and treatment. It found…
New data shows that tuberculosis bacteria develop resistance to fluoroquinolones more frequently than any other drug during treatment.

Questions about Pulmonary Tuberculosis

What factors help differentiate non-tuberculous mycobacterial disease from tuberculosis in patients?

NTM lung disease is more likely in older patients with bronchiectasis, COPD, or diabetes, and often shows thin-walled cavities on CT; TB-IGRA is usually negative in NTM.

Full answer →
How well does a combined radiomics model distinguish tuberculosis from other lung lesions?

A combined radiomics model shows good accuracy (AP 0.85-0.91) for distinguishing tuberculosis from other lung lesions on CT, though performance drops in temporal validation (AP 0.62).

Full answer →
Is the rate of confirmed pulmonary tuberculosis cases dropping in Hunan Province?

Data from Hunan Province shows the rate of confirmed pulmonary tuberculosis cases dropped by an average of 2.2% annually between 2009 and 2023, though the decline slowed after 2017.

Full answer →